Intercept Pharmaceuticals, Inc. et al v. Dr. Reddy's Laboratories, Inc. et al
| Intercept Pharmaceuticals, Inc. and Intercept Pharma Europe LTD. |
| Dr. Reddy's Laboratories, LTD. and Dr. Reddy's Laboratories, Inc. |
| 1:2021cv00035 |
| January 13, 2021 |
| US District Court for the District of Delaware |
| Maryellen Noreika |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on March 12, 2021. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 22
SO ORDERED re (40 in 1:20-cv-01214-MN, 32 in 1:20-cv-01155-MN, 36 in 1:20-cv-01215-MN, 34 in 1:20-cv-01154-MN, 21 in 1:21-cv-00035-MN, 38 in 1:20-cv-01105-MN) Stipulation and Order to Consolidate. ALL FUTURE FILINGS SHALL BE MADE IN C.A. NO. 20-1105. Signed by Judge Maryellen Noreika on 3/12/2021. (dlw)
|
| Case associated with lead case: Create association to 1:20-cv-01105-MN. (dlw) |
|
Filing 21
STIPULATION and Order to Consolidate by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc., Intercept Pharma Europe Ltd.. (Tigan, Jeremy)
|
|
Filing 20
ORAL ORDER Setting Teleconference: Having been advised by the parties of their inability to resolve protective order disputes, IT IS HEREBY ORDERED that a Telephone Conference is set for 4/13/2021 at 12:00 PM before Judge Maryellen Noreika. The opening letter, not to exceed three (3) pages, is due on or before 4/7/2021 and shall attach a copy of the proposed protective order setting forth Plaintiffs' and Defendants' positions. The responsive letter, not to exceed three (3) pages, is due on or before 4/8/2021. Counsel shall provide a dial-in number for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 3/9/2021. (dlw)
|
| Filing 19 NOTICE OF SERVICE of Plaintiffs' Initial Disclosures Identifying Defendants' Accused Products and Plaintiffs' Asserted Patents filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) |
| Filing 18 ANSWER to #10 Answer to Complaint, Counterclaim by Intercept Pharma Europe LTD., Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) |
| Filing 17 STIPULATION TO EXTEND TIME to Submit a Proposed Protective Order to March 5, 2021 - filed by Apotex Corp., Apotex Inc.. (Ormerod, Eve) |
|
SO ORDERED re (37 in 1:20-cv-01214-MN, 31 in 1:20-cv-01154-MN, 17 in 1:21-cv-00035-MN, 32 in 1:20-cv-01105-MN, 33 in 1:20-cv-01215-MN, 29 in 1:20-cv-01155-MN) STIPULATION TO EXTEND TIME to Submit a Proposed Protective Order to March 5, 2021. ORDERED by Judge Maryellen Noreika on 2/26/2021. (dlw)
|
| Pro Hac Vice Attorneys Jovial Wong, Bryce A. Cooper, Alison M. Heydorn for Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, LTD. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd) |
| Filing 16 MOTION for Pro Hac Vice Appearance of Attorney Kevin E. Warner, Jovial Wong, Bryce A. Cooper, and Alison M. Heydorn - filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, LTD.. (Wilson, Samantha) |
| Filing 15 STIPULATION TO EXTEND TIME to Submit Proposed Protective Order to February 26, 2021 - filed by Intercept Pharma Europe LTD., Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) |
|
SO ORDERED re (35 in 1:20-cv-01214-MN, 27 in 1:20-cv-01155-MN, 30 in 1:20-cv-01105-MN, 31 in 1:20-cv-01215-MN, 29 in 1:20-cv-01154-MN, 15 in 1:21-cv-00035-MN) STIPULATION TO EXTEND TIME to Submit Proposed Protective Order to February 26, 2021. ORDERED by Judge Maryellen Noreika on 2/19/2021. (dlw)
|
|
SO ORDERED re #16 MOTION for Pro Hac Vice Appearance of Attorney Kevin E. Warner, Jovial Wong, Bryce A. Cooper, and Alison M. Heydorn filed by Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, LTD., Dr. Reddy's Laboratories, Inc. ORDERED by Judge Maryellen Noreika on 2/19/2021. (dlw)
|
| Filing 14 NOTICE OF SERVICE of 1) Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s Initial Disclosures Pursuant to Rule 26(A)(1) and 2) Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s Disclosures Pursuant to Paragraph 3 of The Default Standard For Discovery filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, LTD..(Wilson, Samantha) |
| Filing 13 NOTICE of Appearance by Samantha G. Wilson on behalf of Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, LTD. (Wilson, Samantha) |
|
SO ORDERED re #12 MOTION for Pro Hac Vice Appearance of Attorney Christopher Sipes, Jeffrey B. Elikan, Megan Keane, Jeremy D. Cobb, Douglas A. Behrens, Laura Dolbow, and Mary Swears filed by Intercept Pharmaceuticals, Inc., Intercept Pharma Europe LTD. ORDERED by Judge Maryellen Noreika on 2/10/2021. (dlw)
|
| Filing 12 MOTION for Pro Hac Vice Appearance of Attorney Christopher Sipes, Jeffrey B. Elikan, Megan Keane, Jeremy D. Cobb, Douglas A. Behrens, Laura Dolbow, and Mary Swears - filed by Intercept Pharma Europe LTD., Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) |
| Filing 11 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Dr. Reddy's Laboratories, Ltd. for Dr. Reddy's Laboratories, Inc. filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, LTD.. (Gaza, Anne) |
| Filing 10 ANSWER to #1 Complaint, , COUNTERCLAIM against Intercept Pharma Europe LTD., Intercept Pharmaceuticals, Inc. by Dr. Reddy's Laboratories, LTD., Dr. Reddy's Laboratories, Inc..(Gaza, Anne) |
| Filing 9 NOTICE OF SERVICE of (1) Plaintiffs' Initial Disclosures Pursuant to Rule 26(A)(1); and (2) Plaintiffs' Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Blumenfeld, Jack) |
| Filing 8 WAIVER OF SERVICE returned executed by Intercept Pharmaceuticals, Inc., Intercept Pharma Europe LTD.: For Dr. Reddy's Laboratories, LTD. waiver sent on 1/25/2021, answer due 3/26/2021. (Blumenfeld, Jack) |
| Filing 7 WAIVER OF SERVICE returned executed by Intercept Pharmaceuticals, Inc., Intercept Pharma Europe LTD.: For Dr. Reddy's Laboratories, Inc. waiver sent on 1/25/2021, answer due 3/26/2021. (Blumenfeld, Jack) |
| Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb) |
| Filing 6 Summonses Issued (please complete the top portion of the form and print out for use/service). (myr) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Intercept Pharma Europe LTD., Intercept Pharmaceuticals, Inc. (myr) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE 48,286 ;9,238,673 ;10,047,117 ;10,052,337 ;10,174,073 ;10,751,349 ;10,758,549. (myr) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No earlier than 12/1/2020. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 11/27/2023. (myr) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (myr) |
| Filing 1 COMPLAINT FOR PATENT INFRINGEMENT filed against Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, LTD. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3461795.) - filed by Intercept Pharmaceuticals, Inc., Intercept Pharma Europe LTD.. (Attachments: #1 Exhibit A-H, #2 Civil Cover Sheet)(myr) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
